Skip to main content
HLS Therapeutics Inc. logo

HLS Therapeutics Inc. — Investor Relations & Filings

Ticker · HLS ISIN · US40390B3078 LEI · 549300QKXFY1J71L2D68 TSX Wholesale and retail trade
Open in API
Filings indexed 364 across all filing types
Latest filing 2022-08-11 Interim / Quarterly Rep…
Country CA Canada
Listing TSX HLS

About HLS Therapeutics Inc.

https://hlstherapeutics.com/

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of branded medicines across North America. The company targets products that address unmet needs, primarily in the treatment of psychiatric disorders and cardiovascular disease/risk reduction. Its commercial-stage portfolio includes CLOZARIL® (clozapine) for psychiatric disorders and VASCEPA® (icosapent ethyl) for cardiovascular risk reduction. HLS also commercializes NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid/ezetimibe combination) for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease. HLS ensures reliable market access to these essential therapies by sourcing products directly from originators and best-in-class manufacturing partners.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of HLS Therapeutics' Q2 Fiscal 2022 financial results, including revenue, EBITDA, net loss, operational highlights, and dividend declaration. It contains comprehensive financial data and analysis for the quarter ended June 30, 2022, and includes management commentary and forward-looking statements. The presence of detailed financial tables, discussion of operating expenses, cash flow, and segment revenues confirms it is a quarterly financial report. The document also mentions a conference call to discuss these results, which is typical for quarterly earnings releases. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q2 2022
2022-08-11 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that HLS Therapeutics Inc. has entered into a Product Listing Agreement with the Saskatchewan Drug Plan for reimbursement coverage of Vascepa. It discusses reimbursement coverage details, product information, company background, and forward-looking statements. There are no financial statements, regulatory filings, or detailed financial data presented. The document is an announcement about a business development related to product reimbursement, not a financial report, regulatory filing, or management discussion. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general regulatory announcement or business update that does not fit other categories, which corresponds to Regulatory Filings (RNS).
2022-08-02 English
News release - English.pdf
Call Transcript Classification · 90% confidence The document is an announcement from HLS Therapeutics about an upcoming conference call to discuss Q2 Fiscal 2022 financial results. It includes details about the date, time, dial-in numbers, webcast link, and replay information. There are no actual financial results or detailed financial data presented in the text. The document is short (2287 characters) and serves to notify investors about the event rather than provide the financial report itself. Therefore, it is not an Earnings Release (ER) or Interim Report (IR), but rather a Call Transcript announcement or conference call notice. Since the document is announcing the conference call and not the transcript itself, the best fitting category is Call Transcript (CT), as it relates to the conference call event and its details.
2022-07-28 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that the pharmaceutical product Vascepa is now reimbursed by Ontario's Provincial Drug Plan, along with other provinces and programs in Canada. It discusses the Product Listing Agreement (PLA) and reimbursement coverage percentages. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The content focuses on a capital/financing update related to reimbursement agreements and market access for a pharmaceutical product, which impacts the company's revenue potential. This fits best under Capital/Financing Update (CAP) as it relates to the company's financing environment and market access rather than a financial report or regulatory filing. The document length is 6288 characters, which is sufficient for a substantive announcement rather than a brief notice or report publication announcement. Therefore, the classification is CAP with high confidence.
2022-07-25 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that HLS Therapeutics has obtained public reimbursement agreements for its drug Vascepa in certain Canadian provinces and programs. It discusses product listing agreements and reimbursement coverage but does not contain any financial statements, detailed financial performance data, or regulatory filings. It is a corporate announcement about reimbursement and market access rather than a financial report or regulatory filing. The content is not related to earnings, management changes, capital updates, or legal proceedings. It is a general corporate news announcement about product reimbursement status. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-06-22 English
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'HLS Therapeutics Reports Annual Meeting Results' and details the voting outcomes from the company's Annual Meeting of Shareholders held on June 17, 2022. It includes specific vote counts and percentages for director nominees and auditor appointment approval. The content focuses solely on the voting results from the Annual General Meeting (AGM) and does not contain financial statements, management discussion, or other report content. The document length is 2350 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document fits the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2022-06-17 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.